BNGO BIONANO GENOMICS INC revenue, earnings and financials
For the quarter ended June 30, 2026, BIONANO GENOMICS INC reported revenue of $8.17M (up 21.4% from a year earlier), net income of −$7.42M and diluted EPS of −$0.64; over the last four quarters revenue was $30.2M and net income −$32.2M; for the fiscal year ended December 2025 revenue was $28.5M, down 7.4% on the year before.
BNGO annual revenue and earnings
- Fiscal year ended Dec 2025: revenue $28.5M, gross profit n/a, operating income −$33.3M, net income −$26.4M (margin -92.6%), EPS −$4.85
- Fiscal year ended Dec 2024: revenue $30.8M, gross profit n/a, operating income −$104M, net income −$112M (margin -364.0%), EPS −$88.13
- Fiscal year ended Dec 2023: revenue $36.1M, gross profit n/a, operating income −$215M, net income −$232M (margin -643.7%), EPS −$408.60
- Fiscal year ended Dec 2022: revenue $27.8M, gross profit n/a, operating income −$132M, net income −$133M (margin -476.9%), EPS −$4.58
- Fiscal year ended Dec 2021: revenue $18.0M, gross profit n/a, operating income −$77.1M, net income −$72.4M (margin -402.8%), EPS −$0.26
BNGO quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue $8.17M (up 21.4% year over year), net income −$7.42M, EPS −$0.64
- Quarter ended Mar 31, 2026: revenue $6.69M (up 3.6% year over year), net income −$8.30M, EPS −$0.76
- Quarter ended Dec 31, 2025 (from the annual report): revenue $7.95M (down 2.6% year over year), net income −$7.93M, EPS −$0.12
- Quarter ended Sep 30, 2025: revenue $7.37M (up 21.3% year over year), net income −$8.50M, EPS −$1.59
- Quarter ended Jun 30, 2025: revenue $6.73M (down 13.4% year over year), net income −$6.86M, EPS −$1.99
- Quarter ended Mar 31, 2025: revenue $6.46M (down 26.4% year over year), net income −$3.10M, EPS −$1.15
- Quarter ended Dec 31, 2024 (from the annual report): revenue $8.16M (down 23.9% year over year), net income −$20.1M, EPS −$7.05
- Quarter ended Sep 30, 2024: revenue $6.07M (down 34.8% year over year), net income −$44.2M, EPS −$30.92
- Quarter ended Jun 30, 2024: revenue $7.77M (down 10.3% year over year), net income −$16.2M, EPS −$14.41
- Quarter ended Mar 31, 2024: revenue $8.77M (up 18.3% year over year), net income −$31.4M, EPS −$35.75
- Quarter ended Dec 31, 2023 (from the annual report): revenue $10.7M (up 30.5% year over year), net income −$43.9M, EPS −$402.91
- Quarter ended Sep 30, 2023: revenue $9.32M (up 29.0% year over year), net income −$113M, EPS −$3.22
- Quarter ended Jun 30, 2023: revenue $8.66M (up 29.9% year over year), net income −$38.9M, EPS −$1.24
- Quarter ended Mar 31, 2023: revenue $7.42M (up 30.2% year over year), net income −$37.1M, EPS −$1.23
- Quarter ended Dec 31, 2022 (from the annual report): revenue $8.22M (up 30.4% year over year), net income −$38.7M, EPS −$2.24
- Quarter ended Sep 30, 2022: revenue $7.22M (up 55.1% year over year), net income −$31.8M, EPS −$1.10
- Quarter ended Jun 30, 2022: revenue $6.67M (up 73.0% year over year), net income −$32.2M, EPS −$1.13
- Quarter ended Mar 31, 2022: revenue $5.70M (up 79.8% year over year), net income −$30.0M, EPS −$0.11
- Quarter ended Dec 31, 2021 (from the annual report): revenue $6.30M, net income −$22.9M, EPS −$0.08
- Quarter ended Sep 30, 2021: revenue $4.66M, net income −$20.8M, EPS −$0.07
BNGO cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$16.3M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$68.9M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$125M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$125M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$71.9M, share buybacks n/a
BNGO balance sheet
- Jun 30, 2026: cash $3.73M, total assets $47.6M, total liabilities $16.0M, shareholders' equity $31.6M
- Mar 31, 2026: cash $3.43M, total assets $64.8M, total liabilities $27.3M, shareholders' equity $37.5M
- Dec 31, 2025: cash $2.99M, total assets $73.6M, total liabilities $29.2M, shareholders' equity $44.4M
- Sep 30, 2025: cash $3.07M, total assets $79.1M, total liabilities $29.3M, shareholders' equity $49.8M
- Jun 30, 2025: cash $3.56M, total assets $76.0M, total liabilities $30.6M, shareholders' equity $45.4M
- Mar 31, 2025: cash $3.63M, total assets $78.4M, total liabilities $30.2M, shareholders' equity $48.2M
- Dec 31, 2024: cash $9.17M, total assets $76.7M, total liabilities $41.3M, shareholders' equity $35.4M
- Sep 30, 2024: cash $8.79M, total assets $87.4M, total liabilities $38.5M, shareholders' equity $48.9M
What is BNGO's revenue?
BIONANO GENOMICS INC reported $30.2M of revenue over its last four quarters, through June 30, 2026.
Is BNGO profitable?
No. BIONANO GENOMICS INC lost $32.2M over the last four quarters.
What is BNGO's EPS?
Diluted earnings per share over the last four quarters were −$3.11; −$0.64 in the latest quarter.